由N6-甲基氨酸诱导的METTL1通过CDK4促进瘤增殖
1Department of Clinical Laboratory, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China.
Biological chemistry
|September 11, 2023
概括
N6 - 甲基亚诺辛 (m6A) 和N7 - 甲基诺辛 (m7G) 的RNA修饰调节了基因表达. 由m6A升高的METTL1通过CDK4的m7G修饰促进头癌,提供潜在的治疗标.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- N6-甲基氨酸 (m6A) 和N7-甲基氨酸 (m7G) 是关键的RNA表观遗传修饰调节基因表达.
- 在癌症发育中m6A和m7G之间的相互作用尚未得到充分理解.
研究的目的:
- 调查m6A甲基转移酶METTL3介导的METTL1在头部和部状细胞癌 (HNSC) 中的作用.
- 阐明METTL1通过与m7G修饰的交叉声调影响癌细胞增殖的机制.
主要方法:
- 数据库挖掘 (GEPIA) 来分析METTL1表达和临床相关性.
- 通过METTL3.3研究METTL1的m6A介导调节.
- 评估METTL1和CDK4对HNSC细胞增殖和细胞周期的功能影响.
- 通过METTL1.4分析CDK4的m7G修饰.
主要成果:
- 在包括HNSC在内的各种癌症中,METTL1被上调,与患者的不良结果相关.
- 通过m6A修改,METTL3增强了METTL1在HNSC中的表达.
- 通过m7G修饰,METTL1通过稳定CDK4促进HNSC细胞增殖和细胞周期进展.
- 过度表达CDK4可以减轻METTL1对癌细胞增殖的抑制作用.
结论:
- METTL1/CDK4轴在HNSC瘤发生中起着至关重要的作用.
- 这项研究揭示了癌症中m6A和m7G修饰之间的新型交叉声机制.
- METTL1/CDK4通路代表了HNSC和其他消化系统瘤的潜在治疗标.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


